Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zimberelimab + domvanalimab + sacituzumab govitecan-hziy + etrumadenant
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A combination anti-cancer regimen consisting of four investigational and approved agents: **zimberelimab** (a fully human anti-PD-1 monoclonal antibody), **domvanalimab** (an Fc-silent anti-TIGIT monoclonal antibody), **sacituzumab govitecan-hziy** (a Trop-2-directed antibody-drug conjugate containing a SN-38 payload), and **etrumadenant** (an oral dual A2a/A2b adenosine receptor antagonist). This combination is in clinical development, primarily for the treatment of advanced solid tumors, including non-small cell lung cancer. Each component employs a distinct immuno-oncology mechanism to enhance anti-tumor immune responses and directly target tumor cells. Arcus Biosciences and its partners are the primary developers; sacituzumab govitecan-hziy (marketed as Trodelvy) is approved for breast cancer and developed by Gilead.
- Brand names
- Trodelvy
- Other names
- zimberelimab + domvanalimab + sacituzumab govitecan-hziy + etrumadenant
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)ADORA2A (Adenosine A₂A Receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)TOP1 (DNA Topoisomerase I)ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on zimberelimab + domvanalimab + sacituzumab govitecan-hziy + etrumadenant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zimberelimab + domvanalimab + sacituzumab govitecan-hziy + etrumadenant.